

aqueous buffer (pH 6.5) containing 0.05% w/w Polysorbate 80 at 37°C, an essentially zero order rate of release of the pharmaceutically active ingredient over a period of 8 hours, the amount of pharmaceutically active ingredient released over eight hours being in the range of 15% to 45%, and when tested in a group of at least five healthy humans the median t_{max}, based on blood sampling at half hourly intervals, is in the range of from about 2.5 to about 6 hours, and the ratio of mean C_{max} to the mean plasma level at 24 hours is in the range of about 1.5 to about 3.5.

3. (Amended) A pharmaceutical dosage form according to claim 1, which has a W₅₀ in the range from about 15 to about 35 hours when tested *in vivo* as set forth in claim 1.
4. (Amended) A pharmaceutical dosage form according to claim 1, wherein the matrix comprises a mixture of an hydrophobic fusible material having a melting point of greater than 40°C and a hydrophilic, organic, polymeric fusible wicking agent.
5. (Amended) A pharmaceutical dosage form according to claim 4, wherein the weight ratio of hydrophobic fusible material to hydrophilic, organic polymeric wicking agent in said mixture is in the range from about 8:1 to about 16:1.
6. (Amended) A pharmaceutical dosage form according to claim 1, in which the pharmaceutically active ingredient is morphine, a pharmaceutically acceptable salt thereof or mixtures thereof.
8. (Amended) A pharmaceutical dosage form according to claim 1, in the form of a tablet or a capsule containing multiparticulates.

9. (Amended) A process for preparing a dosage form according to claim 1 comprising:
- (a) mechanically working in a high shear mixer a mixture of hydrophobic, fusible binder and a minor amount of an organic, fusible, polymeric material which in the finished dosage form is capable of functioning as a wicking agent at a speed and temperature at which the binder melts or softens and the mixture forms agglomerates;
 - (b) extruding the agglomerates whereby the extrudate is obtained as extruded pieces or an elongate extrudate is formed into pieces;
 - (c) continuing mechanically working the pieces in a high shear mixer; and
 - (d) continuing mechanically working with additional binder material at a temperature and speed at which the additional binder melts or softens.
10. (Amended) A process according to claim 9, wherein in stage (d) the additional binder melts or softens and binds with the particles.
11. (Amended) A solid, oral controlled release pharmaceutical dosage form which comprises a pharmaceutically active ingredient having a solubility in water of greater than 1 gm in 250ml water at 25°C dispersed in a matrix, the dosage form being obtainable by a process comprising:
- (a) mechanically working in a high shear mixer a mixture of hydrophobic, fusible binder and a minor amount of an organic, fusible, polymeric material which in the finished dosage form is capable of functioning as a wicking agent at a speed and temperature at which the binder melts or softens and the mixture forms agglomerates;
 - (b) extruding the agglomerates whereby the extrudate is obtained as extruded

pieces or an elongate extrudate is formed into pieces;

(c) continuing mechanically working the pieces in a high shear mixer; and

(d) continuing mechanically working with additional binder material at a temperature and speed at which the additional binder melts or softens.

Please **add** the following new claims as follows:

12. (New) A pharmaceutical dosage form according to claim 1, which has a W_{50} in the range from about 20 to about 30 hours when tested *in vivo* as set forth in claim 1.
13. (New) A pharmaceutical dosage form according to claim 1, in which the pharmaceutically active ingredient is morphine sulfate or morphine hydrochloride.
14. (New) A pharmaceutical dosage form according to claim 4, wherein the median t_{max} is in the range from about 2.5 to about 3.5 hours.
15. (New) A pharmaceutical dosage form according to claim 4, wherein the W_{50} is in a range from about 15 to about 35 hours.
16. (New) A pharmaceutical dosage form according to claim 4, wherein the W_{50} is in a range from about 20 to about 30 hours.
17. (New) A pharmaceutical dosage form according to claim 1, wherein the weight ratio of hydrophobic fusible material to hydrophilic organic polymeric wicking agent in said mixtures in the range from about 8:1 to about 16:1.

18. (New) A pharmaceutical dosage form according to claim 4, wherein the pharmaceutically active ingredient is morphine, a pharmaceutically acceptable salt thereof or mixture thereof.
19. (New) A pharmaceutical dosage form according to claim 4, wherein the pharmaceutically active ingredient is morphine sulfate or morphine hydrochloride.
20. (New) A pharmaceutical dosage form according to claim 5, wherein the pharmaceutically active ingredient is morphine, a pharmaceutically acceptable salt thereof or mixture thereof.
21. (New) A pharmaceutical dosage form according to claim 5, wherein the pharmaceutically active ingredient is morphine sulfate or morphine hydrochloride.
22. (New) A pharmaceutical dosage form according to claim 1, which is suitable for once a day dosing.
23. (New) A pharmaceutical dosage form according to claim 17, which is suitable for once a day dosing.
24. (New) A pharmaceutical dosage form according to claim 4, in the form of a tablet or capsule containing multiparticulates.
25. (New) A pharmaceutical dosage form according to claim 5, in the form of a tablet or capsule containing multiparticulates.